Anticonvulsant and anxiolytic activity of FrPbAII, a novel GABA uptake inhibitor isolated from the venom of the social spider Parawixia bistriata (Araneidae: Araneae)

Brain Research

Volumn 1124, Issue 1, 2006, Pages 19-27

  Liberato, José Luiz ^a   Cunha, Alexandra Olimpio Siqueira ^a   Mortari, Márcia Renata ^a   Gelfuso, Érica Aparecia ^a   de Oliveira Beleboni, René ^b   Coutinho Netto, Joaquim ^a   dos Santos, Wagner Ferreira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

Author keywords

Anticonvulsant; Anxiolytic; FrPbAII polyamine; GABA uptake; GAT1

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; BACLOFEN; BICUCULLINE; FRPBAII TOXIN; GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 2; MUSCIMOL; NIPECOTIC ACID; PARAWIXIA BISTRIATA VENOM; SPIDER VENOM; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID UPTAKE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG ISOLATION; DRUG POTENCY; HIPPOCAMPUS; LIGHT DARK CYCLE; MALE; MAZE TEST; MICROINJECTION; NONHUMAN; PARAWIXIA BISTRIATA; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; RAT STRAIN; SEIZURE; SPIDER; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; ANXIETY; BEHAVIOR, ANIMAL; BICUCULLINE; CHOICE BEHAVIOR; DIAZEPAM; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; HIPPOCAMPUS; MALE; MAZE LEARNING; NEUROPROTECTIVE AGENTS; NIPECOTIC ACIDS; PENTYLENETETRAZOLE; RATS; RATS, WISTAR; SEIZURES; SPIDER VENOMS; SPIDERS; SUBSTANTIA NIGRA; UREA;

ANIMALIA; ARANEAE; ARANEIDAE; RATTUS NORVEGICUS;

EID: 33751270363     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.09.052     Document Type: Article

References (52)

1. Andersen K., Stromgaard K., Krogsgaard-Larsen P., and Jaroszewski J. Recent advances in the medicinal chemistry of polyamine toxins. Mini Rev. Med. Chem. 1 (2001) 317-338
2. Beckman M.L., Bernstein E.M., and Quick M.W. Protein kinase C regulates the interaction between a GABA transporter and syntaxin 1A. J. Neurosci. 18 16 (1998) 6103-6112
3. Beleboni R.O., Pizzo A.B., Fontana A.C.K., Carolino R.O.G., Coutinho-Netto J., and Santos W.F. Spider and wasp neurotoxins: pharmacological and biochemical aspects. Eur. J. Pharmacol. 17 (2004) 1-17
4. Beleboni R.O., Carolino R.O.G., Pizzo A.B., Castellan-Baldan L., Coutinho-Netto J., Santos W.F., and Coimbra N.C. Pharmacological and biochemical aspects of GABAergic neurotransmission: Pathological and neuropsycobiological relationships. Cell. Mol. Neurobiol. 24 6 (2004) 707-728
5. Beleboni R.O., Guizzo R., Fontana A.C.K., Pizzo A.B., Carolino R.O.G., Gobbo-Neto L., Peporine N.L., Coutinho-Netto J., and Santos W.F. Neurochemical characterization of a neuroprotective compound from Parawixia bistriata spider venom that inhibits synaptosomal uptake of GABA and Glycine. Mol. Pharmacol. 69 (2006) 1998-2006
6. Belzung C., Misslin R., Vogel E., Dodd R.H., and Chapouthier G. Anxiogenic effects of methyl-beta-carboline-3-carboxylate in a light/dark choice situation. Pharmarcol. Biochem. Behav. 28 (1987) 29-33
7. Böhme I., and Lüddens H. The inhibitory neural circuitry as target of antiepileptic drugs. Curr. Med. Chem. 8 (2001) 1257-1274
8. Bonina F.P., Aranare L., Palagiano F., Saija A., Nava F., Trombetta D., and de Caprarilis P. Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. J. Pharm. Sci. 88 5 (1999) 561-567
9. Cairrão M.A.R., Ribeiro A.M., Pizzo A.B., Fontana A.C.K., Beleboni R.O., Coutinho-Neto J., Miranda A., and Santos W.F. Anticonvulsant and GABA uptake inhibition properties of P. bistriata and S. raptoria spider venom fractions. Pharm. Biol. 40 6 (2002) 472-477
10. Croucher M.J., Meldrum B.S., and Krogsgaard-Larsen P. Anticonvulsant activity of GABA uptake inhibitors and their prodrugs following central or systemic administration. Eur. J. Pharmacol. 89 3-4 (1983) 217-228
11. Dalby N.O. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 39 12 (2000) 2399-2407
12. Dalby N.O. Inhibition of y-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures. Eur. J. Pharmacol. 479 (2003) 127-137
13. Dalby N.O., Thomsen C., Fink-Jensen A., Lundbeck J., Sokilde B., Man C.M., Sorensen P.O., and Meldrum B. Anticonvulsant properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1. Epilepsy Res. 28 1 (1997) 51-61
14. Durkin M.M., Smith K.E., Borden L.A., Weinshank R.L., Branchek T.A., and Gustafson E.L. Localization of messenger RNAs encoding three GABA transporters in rat brain: an in situ hybridization study. Brain Res. Mol. Brain Res. 33 1 (1995) 7-21
15. Faingold C.L., Randall M.E., and Anderson C.A. Blockade of GABA uptake with tiagabine inhibits audiogenic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsy-prone rat. Exp. Neurol. 126 2 (1994) 225-232
16. Fontana A.C., Guizzo R., Beleboni R.O., Meirelles e Silva A.R., Coimbra N.C., Amara S.G., Santos W.F., and Coutinho-Netto J. Purification of a neuroprotective component of Parawixia bistriata spider venom that enhances glutamate uptake. Br. J. Pharmacol. 139 (2003) 1297-1309
17. Gadea A., and Lopez-Colome A.M. Glial transporters for glutamate, glycine and GABA: II. GABA transporters. J. Neurosci. Res. 63 (2001) 461-468
18. Gale K. GABA in epilepsy: the pharmacologic basis. Epilepsia Suppl. 3 (1989) S1-S11
19. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev. 22 2 (2000) 75-80 (Review)
20. Green A.R., Hainsworth A.H., and Jackson D.M. GABA potentiation: a logical approach for the treatment of acute stroke. Neuropharmacology 39 (2000) 1483-1494
21. Halonen T., Nissinen J., Jansen J.A., and Pitkanen A. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur. J. Pharmacol. 299 1-3 (1996) 69-81
22. Ikegaki N., Saito N., Hashima M., and Tanaka C. Production of specific antibodies against GABA transporter subtypes (GAT1, GAT2, GAT3) and their application to immunocytochemistry. Brain Res. Mol. Brain Res. 26 1-2 (1994) 47-54
23. Iversen L. GABA pharmacology: what prospects for the future?. Biochem. Pharmacol. 68 8 (2004) 1537-1540 (Review)
24. Jonas P., Bischofberger J., and Sandkuhler J. Corelease of two fast neurotransmitters at a central synapse. Science 281 5375 (1998) 419-424
25. Krogsgaard-Larsen P., and Johnston G.A. Inhibition of GABA uptake in rat brain slices by nipecotic acid, various isoxazoles and related compounds. J. Neurochem. 25 6 (1975) 797-802
26. Krogsgaard-Larsen P., Falch E., Larsson O.M., and Schousboe A. GABA uptake inhibitors: relevance to antiepileptic drug research. Epilepsy Res. 1 2 (1987) 77-93 (Review)
27. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92 2 (1987) 180-185
28. Liu Q.R., Lopez-Corcuera B., Mandiyan S., Nelson H., and Nelson N. Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain [corrected]. J. Biol. Chem. 268 (1993) 2106-2112
29. Maggio R., and Gale K. Seizures evoked from Area tempestas are subject to control by GABA and glutamate receptors in substantia nigra. Exp. Neurol. 105 2 (1989) 184-188
30. Maggio R., Sohn E., and Gale K. Lack of proconvulsant action of GABA depletion in substantia nigra in several seizure models. Brain Res. 547 1 (1991) 1-6
31. Mathias S., Wetter T.C., Steiger A., and Lancel M. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol. Aging 22 2 (2001) 247-253
32. McCormick D.A. GABA as an inhibitory neurotransmitter in human cerebral cortex. J. Neurophysiol. 62 (1989) 1018-1027
33. Mellor I.R., and Usherwood P.N.R. Targeting ionotropic receptors with polyamine-containing toxins. Toxicon 43 (2004) 493-508
34. Minelli A., Brecha N.C., Karschin C., DeBiasi S., and Conti F. GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex. J. Neurosci. 15 11 (1995) 7734-7746
35. Mussi-Ribeiro A., Miranda A., Gobbo-Netto L., Peporine L.N., and dos Santos W.F. A anticonvulsive fraction from Scaptocosa raptoria (Araneae: Lycosidae) spider venom. Neurosci. Lett. 371 2-3 (2004) 171-175
36. Nicoll R.A., and Malenka R.C. A tale of two transmitters. Science 281 5375 (1998) 360-361
37. NSE. The National Society of Epilepsy. U.K. (2003). http://www.epilepsynse.org.uk http://www.epilepsynse.org.uk
38. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed. (1986), Academic Press Inc., Sidney
39. Richerson G.B., and Wu Y. Role of the GABA transporter in epilepsy. Adv. Exp. Med. Biol. 548 (2004) 76-91 (Review)
40. Rodrigues M.C.O., Guizzo R., Gobbo-Neto L., Ward R.J., Lopes N.P., and Santos W.F. The biological activity in mammals and insects of the nucleosidic fraction from the spider Parawixia bistriata. Toxicon 43 (2004) 375-383
41. Rosenthal M. Tiagabine for treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J. Clin. Psychiatry 64 10 (2003) 1245-1249
42. Schmitt U., and Hiemke C. Effects of GABA-transporter (GAT) inhibitors on rat behavior in open-field and elevated plus-maze. Behav. Pharmacol. 10 2 (1999) 131-137
43. Schmitt U., Luddens H., and Hiemke C. Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. J. Neural Transm. 109 5-6 (2002) 871-880
44. Schousboe A. Transport and metabolism of glutamate and GABA in neurons are glial cells. Int. Rev. Neurobiol. 22 (1981) 1-45 (Review)
45. Schousboe A., Hjeds H., Engler J., Krogsgaard-Larsen P., and Wood J.D. Tissue distribution, metabolism, anticonvulsant efficacy and effect on brain amino acid levels of the glia-selective gamma-aminobutyric acid transport inhibitor 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol in mice and chicks. J. Neurochem. 47 3 (1986) 758-763
46. Schousboe A., Sarup A., Larsson O.M., and White H.S. GABA transporters as drug targets for modulation of GABAergic activity. Biochem. Pharmacol. 68 8 (2004) 1557-1563
47. Sharma R.P., Martis B., Davis J.M., Omens R., and Janicak P.G. Tiagabine, a specific gamma-aminobutyric acid transporter-1 inhibitor, in the treatment of psychosis. J. Clin. Psychopharmacol. 21 3 (2001) 347-349
48. Suzdak P.D., and Jensen J.A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36 (1995) 612-626
49. Swan M., Najlerahim A., Watson R.E., and Bennett J.P. Distribution of mRNA for the GABA transporter GAT-1 in the rat brain: evidence that GABA uptake is not limited to presynaptic neurons. J. Anat. 185 2 (1994) 315-323
50. Takamori S., Riedel D., and Jahn R. Immunoisolation of GABA-specific synaptic vesicles defines a functionally distinct subset of synaptic vesicles. J. Neurosci. 20 13 (2000) 4904-4911
51. Villetti G., Bregola G., Bassani F., Bergamaschi M., Rondelli I., Pietra C., and Simonato M. Preclinical avaliation of CHF3381 as a novel antiepileptic agent. Neuropharmacology 40 (2001) 866-878
52. White H.S., Sarup A., Bolvig T., Kristensen A.S., Petersen G., and Nelson N. Correlation between anticonvulsant activity and inhibitory action on glial Gaba uptake of the highly selective mouse Gat1 inhibitor 3-hydroxy-4-amino-4,5,6,7-tetrahydro-12-benzisoxazole (Exo-Thpo) and its N-alkylated analogs. J. Pharmacol. Exp. Ther. 302 (2002) 636-644